Two T helper cell clones recognizing the gp 120 envelope protein of HIV were generated from the peripheral blood of a healthy seropositive individual. These cells were type specific as they proliferated and produced IL 2 when stimulated by an epitope in the amino-terminal half of gp 120 of HIVsF2, but not by a similar region of HIVz,6, a Zairian HIV-1 isolate. These two viruses differ by 26% in the deduced amino sequence of the gp 120 protein. Moreover, the antigenic site(s) recognized by the cloned T cells are distinct from those recognized by envelope-specific antibodies. These observations have important implications for the development and use of anti-HIV vaccines.
Introduction
The major external glycoprotein (gp 120) of the HIV is recognized by both neutralizing antibodies (1) and cytotoxic T lymphocytes (2, 3) and, thus, is a prime candidate for use in vaccines against AIDS. Individual isolates of HIV display considerable genetic diversity within the region coding for this protein (4) . Sequence polymorphisms are clustered in a limited number of variable domains that are flanked by conserved regions (5) . Potential antigenic sites that can be recognized by T lymphocytes are present in both regions when the hydrophobicity and predicted secondary structure of the protein are considered (6) . Antiviral T lymphocytes are able to recognize either conserved or variable antigenic sites on viruses such as influenza (7) and herpes simplex virus (8) , but similar patterns of reactivity by human T cells against HIV have not yet been demonstrated. We report here the generation of clonal HIVspecific T helper cell lines, derived from PBMC of a healthy HIV seropositive individual. These cells proliferated and produced IL 2 when stimulated by type-specific epitopes on the gp 120 envelope protein.
Research Laboratories, Emeryville, CA) were produced in the yeast, Sacchromyces cerevisiae, using intracellular expression vectors similar to those described previously (9) . These vectors yield products that are not glycosylated. All of these antigens were insoluble when produced intracellularly in yeast. The recombinant antigens were purified from the insoluble fraction of yeast lysates as described previously for other recombinant HIV-1 envelope polypeptides (9) . Fig. 1 shows the amino acid coordinates of the HIVsF2 (10) or HIVz56 (11) envelope gene products represented by each recombinant polypeptide. The putative signal peptides of HIVSF2 and HIVz56 gp 120 end at amino acid 29 (9, 1 1). The COOH-terminal amino acid of HIVs5 gp 120 is at 509 (9) and HIVzr6 gp 120 is at 5 10 (1 1). Recombinant core p25 protein (gag) of HIVs5 was expressed in an Escherichia coli vector (12) .
Generation of cloned HIV-specific T cell lines. PBMC (1 x 107) from a healthy, HIV seropositive subject were suspended in 1 ml of RPMI culture medium containing 10 ,ug of HIVsF2 env 2-3 peptide, 2.5% IL 2 (Electro-Nucleonics, Inc., Silver Spring, MD), 10% human AB serum (Irvine Scientific, Santa Ana, CA), 2 mM L-glutamine, and antibiotics. Cells were cultured in 24-well tissue culture dishes for 7 d at 37°C in a 5% C02 incubator, and then readjusted to 5 X 106/ml in medium containing 10 ,g/ml env 2-3 and 2.5% IL 2. After an additional 7 d of incubation, the cells were seeded at a concentration of 1 cell/well into 60-well Terasaki plates (Robbins Scientific, Mountain View, CA), along with 1 X 104 irradiated (2,000 R) autologous PBMC, in 0.015 ml of culture medium containing 10 ,ug/ml HIVs5 env 2-3 antigen and 5% IL 2. After expansion, T cells (5 X 102) were restimulated in 16-mm wells at weekly intervals with 2 X 105 irradiated (12,000 R) TM-B cells (as a source of antigen-presenting cells) in culture medium supplemented with 5% IL 2 and 10 ,ug/ml env 2-3 antigen. TM-B is a transformed cell line established by infecting the subject's peripheral blood B cells with cell-free supernatant from the EBV-transformed marmoset cell line B95-6 as described (13 ( 14) .
Antibody ELISA assay. Human sera were assayed for antibodies to each recombinant antigen in an ELISA assay as described (15) (10) .
The antigen specificity of the clones was tested by using a panel of recombinant polypeptides representing different regions of the gp 120 protein from either HIVsF2 (9) or HIVz, 6, a Zairian isolate (Fig. 1, Table I ). The amino acids coded for by the gp 120 gene from each of these two viruses differ by -26% (Steimer, K., unpublished data). Proliferation of both clones was induced by the env 2-3 and env 1, but not the env 4 polypeptide of HIVsF2 (Table I (Table III) . Furthermore, only supernatants from those cultures in which proliferation was detected contained IL 2 (Table III) . Many IL 2-producing human CD4+ T cell lines have the ability to mediate class II HLA-restricted virus-specific cytotoxic activity (7, 8) . More recently, cloned CD4+ cells established from the peripheral blood of chimpanzees infected with recombinant vaccinia viruses that express HIV envelope glycoproteins have been shown to mediate HIV-specific cytotoxic activity (20) . We tested the ability of Serum antibody responses to recombinant HIV antigens. An ELISA assay was used to assess reactivity of various human sera to the recombinant HIV antigens. The values shown for serum 1, the seronegative control, were obtained by averaging the results observed with seven HIV antibody-negative sera assayed in the same experiment. All values reported are the average of duplicate assay wells. Serum 2 is from the subject from whom the cloned cells were generated; sera 3 and 5 are from seropositive American donors; serum 4 is from an HIV seropositive African donor. Sera were considered positive (asterisks) when the OD reading was 2.5 times that of the seronegative control.
clones CL 1O and CL 13 to kill autologous EBV-transformed B cells that were infected with recombinant vaccinia virus that contains the gp 120 coding sequence of HIVs5. Although gp 120 was expressed on the surface of these target cells (as as- sessed by syncytia formation with uninfected CD4+ T cells), no cytotoxic activity was detected (data not shown). Serum antibodies from this subject, in contrast to the two T cell clones, did not react against the env 1 peptide of HIVsF2 in an ELISA assay (Table II) . This result has been observed with sera from many other HIV-infected subjects (Steimer, K., unpublished observation). The finding suggests that the epitopes on gp 120 that are recognized by T cells and by antibodies do not necessarily overlap. The reason for this discordant reactivity is not clear. Class II HLA-restricted T lymphocytes usually recognize antigen only after it has been internalized and processed by antigen-presenting cells; this process destroys the tertiary configuration of the molecule. As a result, T cells generally recognize epitopes that are defined by the primary amino acid sequence of the antigen, whereas antibodies react with conformational epitopes (21) . Thus, improper folding of the env 1 peptide would be more likely to affect recognition by antibodies than T cells. Alternatively, lack of glycosylation of the molecule, which was produced in a yeast vector, may have affected recognition by serum antibodies but not T cells.
A selective defect in the in vitro proliferative response of peripheral blood lymphocytes to whole HIV and its envelope proteins (gp 41 and gp 120) has been observed, particularly in symptomatic individuals (22) (23) (24) . This observation suggested that HIV-specific T helper cell activity is defective in infected individuals (24). The PBMC from the subject from whom the cloned cells were generated also failed to respond in a primary proliferation assay to the envelope peptides (data not shown). Nevertheless, the present results demonstrate for the first time that HIV type-specific T helper cells can be found in the peripheral blood of an infected individual. It is possible that the frequency of these IL 2-producing T helper cells in the peripheral blood was low, and that they were selectively expanded in vitro by incubation with the envelope protein and IL 2. However, the role of HIV-specific T HIV-specific T cell clones such as the ones described here, when used in combination with synthetic peptides, can be useful reagents for defining the conserved and variable antigenic sites that should be included in an anti-HIV vaccine.
